

1282/2023 (unofficial translation)

Decree of the Ministry of Social Affairs and Health on fees chargeable by the Finnish Medicines Agency

By decision of the Ministry of Social Affairs and Health and under section 8 of the Act on Criteria for Charges Payable to the State (150/1992), section 28 of the Medicines Act (395/1987) and section 6 a of the Act on the Finnish Medicines Agency (593/2009), as they appear in section 8 of the Act on Criteria for Charges Payable to the State in Act 348/1994, section 28 of the Medicines Act in Act 773/2009 and in section 6 a of the Act on the Finnish Medicines Agency in Act 1480/2019, the following is enacted:

Section 1

■ *Performances chargeable under public law*

Performances chargeable under public law as defined in section 6 of the Act on Criteria for Charges Payable to the State (150/1992), for which the Finnish Medicines Agency charges fixed fees that correspond to the average costs of the performances as specified in the enclosed table of fees, include the following:

- 1) marketing authorisations, registrations and special licences for medicinal products and veterinary medicinal products;
- 2) variations and other performances pertaining to medicinal products and veterinary medicinal products;
- 3) other authorisations, decisions, certificates and notifications related to pharmacovigilance and regulation of veterinary medicines;
- 4) scientific advice;
- 5) inspections related to the conduct of operations;
- 6) processing the application for approval of an authorised test laboratory as referred to in section 24 of the Chemicals Act (599/2013);
- 7) authorisation required under section 20b of the Act on the Medical Use of Human Organs and Tissues (101/2001), as well as the documents required under section 23a;
- 8) authorisation required under section 4 of the Blood Service Act (197/2005) as well as the authorisation required under section 22 for the import of blood or its components from third countries;
- 9) copies replacing the original decisions or corresponding documents kept at the Finnish Medicines Agency;
- 10) decisions concerning access to documents other than those under sections 9 and 11 of the Act on the Openness of Government Activities (621/1999);
- 11) statements given for the assessment and follow-up of agreements concerning the conditional reimbursement status pursuant to Chapter 6, section 6 a of the Health Insurance Act (1224/2004);
- 12) the authorisations, decisions and certificates issued under the Narcotics Act (373/2008);
- 13) the authorisations and decisions issued under the Act on Mandatory Reserve Supplies (979/2008);
- 14) the permit issued under section 7 of the Act on the Medical Use of Human Organs, Tissues and Cells (101/2001), the permit and decision issued under section 11, the permits and decisions issued under section 19, the authorisation required under section 20b, the permit issued under section 21a, and the authorisation and certificates required under section 23a;

- 15) the decisions issued under the Biobank Act (688/2012) and the processing of notifications, the inspections related to the conduct of operations, and the biobank register maintenance and usage fee;
- 16) the licences granted under section 11 of the Medical Research Act (488/1999);
- 17) authorisations, notifications, applications and certificates, designation and the supervision under Regulation (EU) 2017/745 on medical devices, Regulation (EU) 2017/746 on in vitro diagnostic medical devices and the Medical Devices Act (719/2021).

The fee charged for a performance referred to in section 1 or 2 of the Annex may be waived if the demand for the medicinal product is negligible, but the medicinal product concerned must be deemed essential for treatment.

Section 2

■ *Performances free of charge*

No fee shall be charged for:

- 1) processing and reviewing a notification or authorisation application relating to clinical drug trials in human subjects or clinical trials on a medical device or performance evaluation studies on in vitro diagnostic medical devices or processing and reviewing a notification relating to clinical trials on veterinary medicinal products in animals conducted by an individual investigator, a trial group, a university department, a university hospital clinic, a university veterinary hospital or the Finnish Institute for Health and Welfare if the trial has no outside financing or is financed by a non-profit organisation;
- 2) narcotics licences needed for animal experiments authorised by the Animal Experiment Board;
- 3) narcotics licences needed by the police, customs authorities or customs laboratories engaged in official duties, or for decisions concerning the classification of medicinal products.

In cases set out above in paragraph 1 of subsection 1, the trial notification must be accompanied by a statement to the effect that the trial will not receive any outside financing, or that outside financing will be provided by a non-profit organisation. Medications or medical devices supplied free of charge for use in the trial are not considered external funding.

Notwithstanding the above provisions in subsections 1 and 2, a fee is charged for processing and reviewing a notification or authorisation application relating to a study of a medicinal device if the investigational device has been received free of charge from a third party who has the right to use information produced by the study in its product development or clinical evaluation or performance evaluation of the device.

Section 2a

■ *Waiving of fees or fees charged at less than the cost value*

For special reasons, the Finnish Medicines Agency Fimea may decide to waive a fee referred to in section 1 above or charge it at less than cost price if it is considered justified in view of the overall interest of the state and the equality of the operators.

No processing fee will be charged for a shortage notification if the shortage can be proven to arise from:

- 1) a sudden, unpredictable increase in demand in Finland caused by a pandemic or other special situation;
- 2) a natural disaster that interrupted the production-supply chain,
- 3) a shortage of a competing product, if the market share of the competing product, based on the average sales of the five months prior to the time of notification, is greater than 20 percentage points; or
- 4) a large-scale withdrawal based on a decision by the authorities, which the marketing authorisation holder could not have foreseen.

Section 3

■ *Charging of the fee in certain situations*

The fee referred to in section 1(1) above shall also be charged if a negative decision is given on the application referred to therein.

Section 4

■ *Performances priced according to commercial criteria*

Other performances within the meaning of section 7 of the Act on Criteria for Charges Payable to the State, which the Finnish Medicines Agency shall price according to commercial criteria, include the following:

- 1) information services relating to data and information systems, except for minor guidance and advice;
- 2) training and consultation services;
- 3) commissioned reports, investigations, inspections and analyses;
- 4) publications;
- 5) copies;
- 6) use of the premises occupied by the agency and agency services;
- 7) special services and performances ordered by clients other than, but comparable to, those referred to in points 1–5 above.

Section 5

■ *Other fees*

The fees charged for information retrieval referred to in section 34(2) of the Act on the Openness of Government Activities, and for providing copies and printouts, as defined in section 34(3) of said act, shall be decided by the Finnish Medicines Agency, with due regard to the provisions of section 34 of the Act on the Openness of Government Activities.

Section 6

■ *Entry into force*

This Decree enters into force on 1 January 2024 and will be valid until 31 December 2024.

For performances concerning matters filed prior to the entry into force of this Decree, a fee shall be charged in accordance with the provisions that were in force upon entry into force of this Decree.

In Helsinki on 28 December 2023

Foreign Minister Elina Valtonen

Deputy Director General Tuula Helander

1 MEDICINAL PRODUCTS INTENDED FOR HUMAN USE

1.1 MARKETING AUTHORISATION AND REGISTRATION APPLICATIONS FOR MEDICINAL PRODUCTS INTENDED FOR HUMAN USE

1.1.1 National marketing authorisation and registration procedure for medicinal products intended for human use: application-specific basic fee

Performance	Fee
<ul style="list-style-type: none"> ▪ New active substance/known active substance (Dir. 2001/83/EC, Article 8) ▪ Applications based on established medicinal use (Dir. 2001/83/EC, Article 10 (a)) ▪ Combination products (Dir. 2001/83/EC, Article 10(b)) ▪ Applications for similar biological medicinal products (Dir. 2001/83/EC, Article 10.4) ▪ Homeopathic products subject to marketing authorisation for which a medicinal purpose is stated (Dir. 2001/83/EC, Article 16) <p>For the first marketing authorisation applied for</p> <p>Subsequent pharmaceutical forms or strengths</p>	<p>EUR 18,750</p> <p>EUR 11,000</p>
<ul style="list-style-type: none"> ▪ Applications where the applicant has obtained the consent of the original marketing authorisation holder to refer to the marketing authorisation documentation (Dir. 2001/83/EC, Article 10c) ▪ Generic products (Dir. 2001/83/EC, Article 10.1) ▪ Abridged applications of mixed type (Dir. 2001/83/EC, Article 10.3) <p>For each marketing authorisation or registration applied for</p>	<p>EUR 12,500</p>
<ul style="list-style-type: none"> ▪ Traditional herbal medicinal products to be registered (Dir. 2004/24/EC) ▪ Herbal medicinal products subject to marketing authorisation for which a community monograph exists (Dir. 2004/27/EC, Article 10a) <p>For each marketing authorisation or registration applied for</p>	<p>EUR 6,600</p>
<ul style="list-style-type: none"> ▪ Extensions to a marketing authorisation and registration (Commission Regulation (EC) No 1234/2008) <p>For each marketing authorisation or registration applied for</p>	<p>EUR 11,000</p>
<ul style="list-style-type: none"> ▪ Homeopathic products subject to marketing authorisation for which no medicinal purpose is stated, including marketing authorisation extensions (Dir. 2001/83/EC, Article 16) <p>For each marketing authorisation or registration applied for</p> <ul style="list-style-type: none"> ▪ Homeopathic products subject to registration, including registration extensions (Dir. 2001/83/EC, Article 14) <p>Products containing 1 to 5 parent compounds</p> <p>Products containing more than 5 parent compounds</p>	<p>EUR 2,310</p> <p>EUR 1,050</p> <p>EUR 1,320</p>

1.1.2 Mutual recognition procedure or decentralised procedure for medicinal products, Finland as a Concerned Member State: application-specific basic fee

Performance	Fee
<ul style="list-style-type: none"> ▪ New active substance/known active substance (Dir. 2001/83/EC, Article 8) ▪ Applications based on established medicinal use (Dir. 2001/83/EC, Article 10 (a)) ▪ Combination products (Dir. 2001/83/EC, Article 10(b)) ▪ Applications for similar biological medicinal products (Dir. 2001/83/EC, Article 10.4) 	

Performance	Fee
<ul style="list-style-type: none"> Homeopathic products subject to marketing authorisation for which a medicinal purpose is stated (Dir. 2001/83/EC, Article 16) <p>For the first marketing authorisation applied for</p> <p>Subsequent pharmaceutical forms or strengths</p>	<p>EUR 11,000</p> <p>EUR 6,600</p>
<ul style="list-style-type: none"> Applications where the applicant has obtained the consent of the original marketing authorisation holder to refer to the marketing authorisation documentation (Dir. 2001/83/EC, Article 10c) Generic products (Dir. 2001/83/EC, Article 10.1) Abridged applications of mixed type (Dir. 2001/83/EC, Article 10.3) <p>For each marketing authorisation or registration applied for</p>	<p>EUR 6,600</p>
<ul style="list-style-type: none"> Traditional herbal medicinal products to be registered (Dir. 2004/24/EC) Herbal medicinal products subject to marketing authorisation for which a community monograph exists (Dir. 2004/27/EC, Article 10a) <p>For each marketing authorisation or registration applied for</p>	<p>EUR 6,600</p>
<ul style="list-style-type: none"> Extensions to a marketing authorisation and registration (Commission Regulation (EC) No 1234/2008) <p>For each marketing authorisation or registration applied for</p>	<p>EUR 6,600</p>
<ul style="list-style-type: none"> Homeopathic products subject to marketing authorisation for which no medicinal purpose is stated, including marketing authorisation extensions (Dir. 2001/83/EC, Article 16) <p>For each marketing authorisation or registration applied for</p> <ul style="list-style-type: none"> Homeopathic products subject to registration, including registration extensions (Dir. 2001/83/EC, Article 14) <p>Products containing 1 to 5 parent compounds</p> <p>Products containing more than 5 parent compounds</p>	<p>EUR 2,310</p> <p>EUR 1,050</p> <p>EUR 1,320</p>

1.1.3 Mutual recognition procedure or decentralised procedure for medicinal products for human use, Finland as the Reference Member State: process fee

Performance	Fee
<p>Process fee for a mutual recognition procedure</p> <p>The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.</p>	<p>EUR 13,200</p>
<p>0-day process fee for a mutual recognition procedure without updating the assessment report</p> <p>The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.</p>	<p>EUR 4,400</p>
<p>Process fee for a decentralised procedure</p> <p>In addition to the process fee, a basic fee according to section 1.1.1 (National marketing authorisation and registration procedure for medicinal products for human use) for each marketing authorisation or registration applied for.</p> <p>The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.</p> <p>The process fee and application fee will be charged when the application has been accepted for processing.</p>	<p>EUR 15,000</p>

1.1.4 Marketing authorisation for medicinal products for human use, parallel import

Performance	Fee
For the first source country	EUR 2,090
For each subsequent source country	EUR 1,210

1.2 VARIATION APPLICATIONS FOR MEDICINAL PRODUCTS INTENDED FOR HUMAN USE

The fees specified below will be charged separately for each marketing authorisation and registration. If an identical variation of other pharmaceutical forms and/or strengths of the same trade name is being applied for in one application, the fee will only be charged for one marketing authorisation or registration.

In the grouping of the variations (G), the processing fee pursuant to the Decree will be payable for each variation. This does not apply to a grouped application for variations concerning the trade name, for which the processing fee will only be charged one.

In the worksharing procedure (WS), the processing fee pursuant to the Decree is payable for each variation applied for. The processing fee is payable depending on Finland's role in the process concerned.

1.2.1 National marketing authorisation or registration of medicinal products for human use: processing fee

Performance	Fee
Type II variations (Commission Regulation (EC) No 1234/2008)	
Addition of a therapeutic indication	EUR 4,400
Other type II variations	EUR 1,250
Type IB variations	EUR 475

1.2.2 Mutual recognition procedure for medicinal products for human use, Finland as a Concerned Member State: processing fee

Performance	Fee
Type II variations (Commission Regulation (EC) No 1234/2008)	
Addition of a therapeutic indication	EUR 3,300
Other type II variations	EUR 880
Type IB variations	EUR 375

1.2.3 Mutual recognition procedure for medicinal products for human use, Finland as Reference Member State: process fee

Performance	Fee
Type II variations (Commission Regulation (EC) No 1234/2008)	EUR 2,200
Process fee	
Additionally, a processing fee in accordance with section 1.2.1 (National marketing authorisation or registration of medicinal products for human use)	EUR 990
Type IB variations	
Process fee	
Additionally, a processing fee in accordance with section 1.2.1 (National marketing authorisation or registration of medicinal products for human use)	
Type IA variations	EUR 625
Process fee	

Performance	Fee
For grouped variation applications, the process fee is only paid once based on the most significant variation (II/IB/IA). An exception to the above are type IA grouped variation applications that include several processes.	
Type IA grouped variation applications including more than one process (FI/H/XXXX/IA/G) Process fee	EUR 1,100
Worksharing procedure Process fee Additionally, a processing fee in accordance with section 1.2.1 (National marketing authorisation or registration of medicinal products for human use)	EUR 4,400

1.2.4 Parallel import of medicinal products for human use

Performance	Fee
Type II variations (Commission Regulation (EC) No 1234/2008)	EUR 660
Type IB variations	EUR 275

1.2.5 Transfer of marketing authorisation or registration of medicinal products for human use to a new holder

Performance	Fee
Transfer of a marketing authorisation or registration to another holder	EUR 200

1.3 ANNUAL FEES FOR MEDICINAL PRODUCTS INTENDED FOR HUMAN USE

Performance	Fee
<ul style="list-style-type: none"> ▪ The fee is charged for each marketing authorisation and registration. ▪ The annual fee includes the cost of register maintenance, medicines information produced by the Finnish Medicines Agency, adverse effect monitoring with the associated Periodic Safety Update Reports (PSUR), processing of product defects, renewal of a marketing authorisation or registration, processing of Type IA applications, monitoring of medicinal product advertising, maintenance of ATC classification and DDD registers, and medicine consumption statistics. ▪ The fee is determined according to the average costs arising from the performance of the above duties for each marketing authorisation or registration. 	
Medicinal products referred to in sections 21–21c and 21e of the Medicines Act	
Parallel import products	EUR 1,550
Registered traditional herbal medicinal products	EUR 880
Herbal medicinal products, homeopathic and anthroposophic products subject to marketing authorisation	EUR 220
Registered homeopathic and anthroposophic products	EUR 220

1.4 RENEWAL OF A MARKETING AUTHORISATION OF MEDICINAL PRODUCTS FOR HUMAN USE

1.4.1 Mutual recognition procedure for medicinal products for human use, Finland as the Reference Member State: process fee

Performance	Fee
<p>A process fee is charged for renewal when Finland acts as a Reference Member State in a mutual recognition procedure.</p> <p>The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.</p>	
Renewal process fee	EUR 1,100
Renewal process fee, extended renewal application	EUR 2,200

1.5 APPLICATION FOR EXEMPTION TO MARKETING AUTHORISATION AND REGISTRATION OF MEDICINAL PRODUCTS FOR HUMAN USE

1.5.1 Application for exemption to marketing authorisation or registration of medicinal products under section 29(3) of the Medicines Act

Performance	Fee
<p>Application for an exemption (Sunset Clause)</p> <p>The fee includes all pharmaceutical forms and/or strengths of the same trade name.</p>	EUR 100

2 VETERINARY MEDICINAL PRODUCTS

2.1 MARKETING AUTHORISATION AND REGISTRATION APPLICATIONS FOR VETERINARY MEDICINAL PRODUCTS

2.1.1 National marketing authorisation and registration procedure for veterinary medicinal products: application-specific basic fee

Performance	Fee
<ul style="list-style-type: none"> ▪ Complete application/known active substance (Regulation (EU) 2019/6, Article 8) ▪ Application based on bibliographic data (Regulation 2019/6, Article 22) ▪ Combination veterinary medicinal products (Regulation 2019/6, Article 20) ▪ Homeopathic medicinal products subject to marketing authorisation for which a medicinal purpose is stated (Regulation 2019/6, Article 5) <p>For the first marketing authorisation applied for</p> <p>Subsequent pharmaceutical forms or strengths</p>	<p>EUR 10,750</p> <p>EUR 6,600</p>
<ul style="list-style-type: none"> ▪ Application based on informed consent (Regulation 2019/6, Article 21) ▪ Generic veterinary medicinal products (Regulation 2019/6, Article 18) ▪ Hybrid veterinary medicinal products (Regulation 2019/6, Article 19) <p>For each marketing authorisation applied for</p>	EUR 6,600
<ul style="list-style-type: none"> ▪ Applications for limited markets (Regulation 2019/6, Article 23) ▪ Applications in exceptional circumstances (Regulation 2019/6, Article 25) <p>For each marketing authorisation applied for</p>	EUR 5,500
<ul style="list-style-type: none"> ▪ Registration of homeopathic veterinary medicinal products (Regulation 2019/6, Article 86) <p>Products containing 1 to 5 parent compounds</p>	EUR 940

Performance	Fee
Products containing more than 5 parent compounds	EUR 1,210

2.1.2 Mutual recognition procedure, subsequent recognition or decentralised procedure for veterinary medicinal products, Finland as a Concerned Member State: application-specific basic fee

Performance	Fee
<ul style="list-style-type: none"> ▪ Complete application/known active substance (Regulation 2019/6, Article 8) ▪ Application based on bibliographic data (Regulation 2019/6, Article 22) ▪ Combination veterinary medicinal products (Regulation 2019/6, Article 20) ▪ Homeopathic veterinary medicinal products subject to marketing authorisation for which a medicinal purpose is stated (Regulation 2019/6, Article 5) <p>For the first marketing authorisation applied</p> <p>For Subsequent pharmaceutical forms or strengths</p>	<p>EUR 10,450</p> <p>EUR 4,950</p>
<ul style="list-style-type: none"> ▪ Application based on informed consent (Regulation 2019/6, Article 21) ▪ Generic veterinary medicinal products (Regulation 2019/6, Article 18) ▪ Hybrid veterinary medicinal products (Regulation 2019/6, Article 19) <p>For each marketing authorisation applied for</p>	EUR 4,950
<ul style="list-style-type: none"> ▪ Applications for limited markets (Regulation 2019/6, Article 23) ▪ Applications in exceptional circumstances (Regulation 2019/6, Article 25) <p>For each marketing authorisation applied for</p>	EUR 3,850

2.1.3 Mutual recognition procedure, subsequent recognition or decentralised procedure for veterinary medicinal products, Finland as the Reference Member State: process fee

Performance	Fee
<p>Process fee for a mutual recognition procedure</p> <p>The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.</p> <p>0-day process fee for a mutual recognition procedure without updating the assessment report</p> <p>The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.</p>	<p>EUR 13,200</p> <p>EUR 4,400</p>
<p>Process fee for a decentralised procedure</p> <p>In addition to the process fee, a basic fee according to section 2.1.1 (National marketing authorisation procedure for veterinary medicinal products) for each marketing authorisation</p> <p>The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.</p> <p>The process fee and application fee will be charged when the application has been accepted for processing.</p>	EUR 13,200
<p>Subsequent recognition of marketing authorisations</p> <p>The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.</p>	EUR 13,200

2.1.4 Authorisation of parallel trade in veterinary medicinal products (Regulation 2019/6, Article 102)

Performance	Fee
For the first source country	EUR 2,090
For each subsequent source country	EUR 1,210

2.2 VARIATION APPLICATIONS FOR VETERINARY MEDICINAL PRODUCTS

The fees specified below will be charged separately for each marketing authorisation and registration. If an identical variation of other pharmaceutical forms and/or strengths of the same trade name is being applied for in one application, the fee will only be charged for one marketing authorisation or registration.

In the grouping of the variations (G), the processing fee pursuant to the Decree on Fees will be payable for each variation. This does not apply to a grouped application for variations concerning the trade name, for which the processing fee will only be charged one.

In the worksharing procedure (WS), the processing fee pursuant to the Decree on Fees is payable for each variation applied for. The processing fee is payable depending on Finland's role in the process concerned.

2.2.1 Variation applications for veterinary medicinal products, national marketing authorisation or registration: processing fee

Performance	Fee
Variation applications requiring assessment	
Extended schedule1*	EUR 4,240
Standard schedule2*	EUR 880
Reduced schedule	EUR 375
Variation application for a nationally registered homeopathic veterinary medicinal product	EUR 1,000
1* For example, addition of a therapeutic indication or target species, changes in active substance(s), strength, pharmaceutical form or route of administration	
2) Including a change of the withdrawal period	

2.2.2 Variation applications for veterinary medicinal products, mutual recognition procedure, Finland as a Concerned Member State

Performance	Fee
Variation applications requiring assessment	
Extended schedule	EUR 3,410
Standard schedule	EUR 660
Reduced schedule	EUR 275

2.2.3 Variation applications for veterinary medicinal products, mutual recognition procedure, Finland as the Reference Member State: process fee

Performance	Fee
Variation applications requiring assessment	
▪ Extended schedule	
▪ Standard schedule	
Process fee	
Additionally, a processing fee in accordance with section 2.2.1 (National marketing authorisation of veterinary medicinal products)	EUR 2,200
Variation applications requiring assessment	
▪ Reduced schedule	
Process fee	
Additionally, a processing fee in accordance with section 2.2.1 (National marketing authorisation of veterinary medicinal products)	EUR 990
Worksharing procedure	

Performance	Fee
Process fee Additionally, a processing fee in accordance with section 2.2.1 (National marketing authorisation of veterinary medicinal products)	EUR 4,400

2.2.4 Transfer of marketing authorisation or registration of veterinary medicinal products to a new holder

Performance	Fee
Transfer of a marketing authorisation or registration to another holder	EUR 200

2.2.5 Variation applications for veterinary medicinal products, parallel trade

Performance	Fee
<ul style="list-style-type: none"> ▪ Type II variations ▪ Type IB variations 	EUR 660 EUR 275

2.3 ANNUAL FEES FOR VETERINARY MEDICINAL PRODUCTS

Performance	Fee
<ul style="list-style-type: none"> ▪ The fee is charged for each marketing authorisation and registration. ▪ The annual fee includes the cost of register maintenance, medical information produced by the Finnish Medicines Agency, adverse effect monitoring, processing of product defects, processing of variation applications not requiring an assessment, processing of Type IA variation applications for parallel trade products, monitoring of medicinal product advertising, maintenance of ATC classification and DDD registers, and medicine consumption statistics. ▪ In the case of a national marketing authorisation granted based on applications for limited markets and in exceptional circumstances, the annual fee also includes the re-examination procedure. ▪ The fee is determined according to the average costs arising from the performance of the above duties for each marketing authorisation or registration. 	
Annual fee for a veterinary medicinal product subject to marketing authorisation	EUR 1,550
Annual fee for homeopathic veterinary medicinal products registered for veterinary use and subject to marketing authorisation	EUR 220
Annual fee for a parallel trade permit	EUR 750

2.4 RE-EXAMINATION PROCEDURE FOR MARKETING AUTHORISATION OF A VETERINARY MEDICINAL PRODUCT

2.4.1 Mutual recognition procedure for veterinary medicinal products, Finland as the Reference Member State: process fee

Performance	Fee
The re-examination procedure pertains to applications for limited markets and in exceptional circumstances.	

Performance	Fee
<p>A process fee is charged for the re-examination procedure when Finland acts as the Reference Member State in the mutual recognition procedure.</p> <p>The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.</p> <p>Process fee for re-examination procedure</p>	<p>EUR 2,200</p>

3 SCIENTIFIC ADVICE

Performance	Fee
Scientific advice on medicinal products for human use	EUR 5,500
Scientific advice on veterinary medicinal products	EUR 830

4 SPECIAL AUTHORISATIONS AND CLASSIFICATION

Performance	Fee
Authorisation (special authorisation) referred to in section 21f of the Medicines Act	EUR 20
Patient-specific special authorisations requiring urgent processing	EUR 40
Special authorisations for veterinary medicinal products requiring urgent processing	EUR 40
Institution-specific authorisation (special authorisation) referred to in section 21f of the Medicines Act	EUR 40
Institution-specific special authorisations requiring urgent processing	EUR 80
Product classification decisions	EUR 550

5 EXPORT CERTIFICATES

Performance	Fee
Certificates concerning industrial manufacture and wholesale of medicinal products for human and veterinary use related to their export	
A certificate requested in regular schedule	EUR 165
Request for express delivery of a certificate with a delivery time less than 2 weeks from the order	EUR 330
Medical device, certificate of free sale	
First copy	EUR 165
Duplicates ordered in the same connection	EUR 35
Request for express delivery of a certificate of free sale for a medical device with a delivery time of less than 2 weeks from the order	EUR 330
First copy	EUR 65
Duplicates ordered in the same connection	
Official certificate of devices in the medical device register	EUR 165
First copy	EUR 35
Duplicates ordered in the same connection	

6 OTHER AUTHORISATIONS, REGISTRATIONS, DECISIONS, CERTIFICATES AND NOTIFICATIONS RELATED TO PHARMACOVIGILANCE

Performance	Fee
Processing of applications related to veterinary clinical trials (Regulation 2019/6, Article 9)	EUR 880
Notification of a substantial modification to a clinical trial protocol	EUR 990
Application for a substantial modification to a clinical trial protocol	EUR 265
Processing of a shortage notification made pursuant to section 27 of the Medicines Act	EUR 280
Licences or registrations concerning industrial manufacture of medicinal products, veterinary medicinal products and active substances, pharmaceutical wholesaling and manufacture of advanced therapy medicinal products, registration concerning the distribution of medicinal products, and changes to licences and registrations:	
Licence for the industrial manufacture of medicinal and veterinary products (Medicines Act, section 8; Veterinary Medicines Regulation, Article 88)	EUR 3,300
Licence for the contract analysis of medicinal and veterinary products (Medicines Act, section 10; Veterinary Medicines Regulation, Article 88)	EUR 1,650
Licence for the manufacture of medicinal or veterinary products for clinical trials and/or veterinary clinical trials (Medicines Act, section 15 a)	EUR 1,650
Manufacturing authorisation of advanced therapy medicinal products (Medicines Act, sections 8 and 15c)	EUR 1,650
Registration of the manufacturer of the active substance of a veterinary medicine	EUR 2,200
Manufacturer of an API/active substance used in a veterinary clinical trial	EUR 1,100
Changes to registration data	EUR 550
Pharmaceutical wholesale licence for medicinal or veterinary products	EUR 1,925
Pharmaceutical wholesale licence for anthroposophic and homeopathic products	EUR 1,100
Registration of the EEA importer and distributor of the active substance of a veterinary medicinal product	EUR 1,100
The fee will not be charged to licence holders who import APIs/active substances for their in-house manufacture referred to in section 8 of the Medicines Act or Article 88 of Regulation (EU) 2019/6.	
Changes to registration data	EUR 550
Registration of a distributor of medicinal products	EUR 1,100
If an application for an operating licence, registration, or a change thereto requires pre-inspection, the inspection will be subject to a separate charge.	
Operating licences for tissue establishments or blood service operations and changes to them	EUR 3,300
Import and export licences related to tissue establishments or blood service operations	EUR 550
Import certificate related to tissue establishment operations	EUR 550
Patient-specific import and export licences	EUR 110
If the application for an operating licence or for changes to an operating licence requires pre-inspection, the inspection will be subject to a separate charge.	
Pharmacy licence	EUR 5,500
Pharmacy service point licence	EUR 1,380
Running a pharmacy service point as a precondition for a pharmacy licence	EUR 1,380
Short-term pharmacy service point licence (duration less than 1 month)	EUR 550
Subsidiary pharmacy authorisation	EUR 2,750

Performance	Fee
Running a subsidiary pharmacy as a precondition for a pharmacy licence	EUR 2,750
Changing the location area of a subsidiary pharmacy at the subsidiary pharmacy authorisation holder's request	EUR 2,750
Processing of a prior notification of a pharmacy web service or other means of distance communication	EUR 1,100
Processing of an application for the use of each following means of distance communication by the pharmacy	EUR 440
Extension of the time limit granted for pharmacy business	EUR 1,100
Granting a pharmacy licence pursuant to section 54(2) of the Medicines Act	EUR 5,500
Authorisation for setting up a hospital pharmacy, dispensary or military pharmacy	EUR 5,500
Licence for non-industrial manufacture under section 12a of the Medicines Act	EUR 2,200
Authorisation referred to in section 62 of the Medicines Act to supply medicinal products, except for the supply of medicines for the treatment of an individual patient or for the supply of vaccines for the prevention of communicable diseases under the Communicable Diseases Act	EUR 1,100
A licence to store less medicines/veterinary medicines than the statutory minimum or to store APIs/active substances instead of medicinal products, for each product applied for Application filed at least 2 weeks prior to the date of commencement of the underrun or replacement applied for Application filed less than 2 weeks prior to the date of commencement of the underrun or replacement applied for	EUR 600 EUR 1,200
Exemption from maintaining mandatory reserve supplies or alternate way of maintaining mandatory reserve supplies; as a whole or for each group of medicinal/veterinary products containing the same API/active substance Application filed at least 2 weeks prior to the date of commencement of the exemption or alternative arrangement applied for Application filed less than 2 weeks prior to the date of commencement of the exemption or alternative arrangement applied for	EUR 660 EUR 1,320
Licences and decisions in accordance with the Narcotics Act including decisions on the registration of operations and persons in charge and licences concerning substances used in drug manufacturing with the exception of licences required for the treatment of an individual patient	EUR 220
Clearance certificates for the import of pharmaceuticals, narcotics or precursors of narcotics required by other countries	EUR 110
Decision concerning approval of a GLP testing laboratory and changes to the decision	EUR 1,100

7 INSPECTIONS RELATED TO THE CONDUCT OF OPERATIONS

In inspections carried out abroad, the fee for additional days will be charged for each member of the inspection team who travelled on site, and in addition to the inspection fee, the actual travel and accommodation costs as well as potential interpretation costs will be charged.

The charge for remote inspections performed in real time over a remote connection, in part or in whole, is the same as if the entire inspection was performed on site. If the target of inspection is located in Finland, the fee for an inspection performed entirely as a remote inspection is discounted by 10%.

The inspection fee chargeable for the first day plus actual travel and interpretation service costs will be charged for each and every inspection cancelled on the operator's initiative after the inspection was agreed upon in writing and the preparations were started.

Performance	Fee
<p>Inspections related to clinical trials on medicinal or veterinary products</p> <p>For 1 day Additional days</p> <p>In inspections carried out abroad, the fee for additional days will be charged for each member of the inspection team who travelled on site</p>	<p>EUR 6,600 EUR 3,300</p>
<p>Inspection of pharmacovigilance</p> <p>For 1 day Additional days</p> <p>In inspections carried out abroad, the fee for additional days will be charged for each member of the inspection team who travelled on site</p>	<p>EUR 4,400 EUR 2,200</p>
<p>Inspection of a marketing authorisation holder of a medicinal or veterinary product and a registration holder of traditional herbal medicinal product</p> <p>For 1 day Additional days</p>	<p>EUR 4,400 EUR 2,200</p>
<p>Inspection of a medicinal/veterinary medicinal product plant, API/active substance manufacturer or excipient manufacturer</p> <p>For 1 day Additional days</p> <p>In inspections carried out abroad, the fee for additional days will be charged for each member of the inspection team who travelled on site</p> <p>Inspection of a medicinal/veterinary medicinal product plant, API/active substance manufacturer or excipient manufacturer carried out at the operator's own request</p> <p>For 1 day Additional days for each member of the inspection team who travelled on site</p>	<p>EUR 7,200 EUR 3,600</p> <p>EUR 11,000 EUR 5,500</p>
<p>Inspection of an operator manufacturing medicinal products, veterinary medicinal products or active substances for clinical trials or veterinary clinical trials and a laboratory engaged in contract analysis, domestic</p> <p>For 1 day Additional days</p> <p>Inspection of an operator manufacturing medicinal products for clinical trials or veterinary clinical trials and a laboratory engaged in contract analysis, abroad</p> <p>For 1 day Additional days for each member of the inspection team who travelled on site</p>	<p>EUR 3,300 EUR 1,650</p> <p>EUR 6,600 EUR 3,300</p>
<p>Inspection of a pharmaceutical and veterinary product wholesaler</p> <p>For 1 day Additional days</p> <p>Inspection of pharmaceutical wholesaling targeted at a single area of operations with duration of no more than 4 hours</p> <p>Inspection of a pharmaceutical and veterinary product wholesaler, if the operations do not include warehousing and possession of medicinal or veterinary products or if the warehousing and possession is only limited to homeopathic products or samples of pharmaceuticals or pharmaceutical preparations referred to in section 35(2) of the Medicines Act that are not intended for human or veterinary use</p> <p>For 1 day Additional days</p>	<p>EUR 6,600 EUR 3,300 EUR 3,300</p> <p>EUR 4,400 EUR 2,200</p>
<p>Inspection of pharmaceutical wholesaling targeted at a single area of operations with duration of no more than 4 hours</p>	<p>EUR 2,200</p>

Performance	Fee
Inspection of an anthroposophic or homeopathic product wholesaler or inspection of a medicinal product distributor For 1 day Additional days	EUR 2,200 EUR 1,100
Inspection of an EEA importer and/or distributor of APIs/active substances conducted separately	EUR 3,300
Inspection of blood service and tissue establishment operations and an organ transplantation centre For 1 day Additional days Inspection of blood service or tissue establishment operations targeted at a single area of operations with duration of no more than 4 hours Inspection of tissue establishment operations based on documents	EUR 3,300 EUR 1,650 EUR 2,200 EUR 1,100
Inspection of an organ donation hospital Inspection of an organ donation hospital based on documents	EUR 2,200 EUR 1,100
Inspection related to the manufacturing authorisation of an advanced therapy medicinal product manufactured under a national manufacturing authorisation For 1 day Additional days	EUR 3,300 EUR 1,650
Inspection of a pharmacy, hospital pharmacy, military pharmacy or dispensary For 1 day Additional days Inspection targeted at a single operation with a duration of no more than 4 hours Inspection of a subsidiary pharmacy In connection with the main pharmacy inspection As a separate inspection	EUR 4,400 EUR 2,200 EUR 2,200 EUR 2,200 EUR 3,300
Inspection related to the approval or supervision of a GLP test laboratory, domestic For 1 day Additional days Inspection targeted at a single operation with a duration of no more than 4 hours Inspection related to the approval or supervision of a GLP test laboratory, rest of the world For 1 day Additional days for each member of the inspection team who travelled on site	EUR 4,400 EUR 2,200 EUR 2,200 EUR 6,600 EUR 3,300
A fee is charged for the following inspections when no inspection under the Medicines Act is carried out in connection with the inspection: Inspections performed under legislation on narcotics or mandatory reserve supplies For 1 day Additional days	EUR 2,200 EUR 1,100
Inspection of the recording system of safety features of a medicinal product and the maintainer of the recording system	EUR 6,600
Inspection of a biobank's facilities and operations For 1 day Additional days	EUR 2,750 EUR 1,380
Inspection of the operations of a unit that researches embryos pursuant to section 11 of the Medical Research Act (488/1999) or provides teaching pursuant to section 11 of the Act of the Medical Use of Human Organs and Tissues (101/2001) For each inspection day Inspection based on documents	EUR 1,100 EUR 550

Performance	Fee
Inspection of manufacturers of medical devices and products listed in Annex XVI to the MD Regulation (EU) 2017/745	
For 1 day	EUR 5,500
Additional days	EUR 2,750
Inspection with total duration of no more than 4 hours	EUR 2,750
Inspection based on documents	EUR 2,200
Inspections of authorised representatives, manufacturers, importers, system and procedure pack assemblers, sterilisation service providers and distributors of medical devices	EUR 2,750
For 1 day	EUR 1,650
Additional days	EUR 1,650
Inspection with total duration of no more than 4 hours	EUR 1,100
Inspection based on documents	
Inspection of in-house manufacture of devices by professional users and health care units	EUR 2,750
For 1 day	EUR 1,650
Additional days	EUR 1,650
Inspection with total duration of no more than 4 hours	
Inspection of clinical device investigations and performance studies on IVD devices	EUR 6,000
For 1 day	EUR 3,000
Additional days	EUR 3,000
Inspection with total duration of no more than 4 hours	

8 ASSESSMENT AND FOLLOW-UP OF AGREEMENTS ON CONDITIONAL REIMBURSEMENT OF A MEDICINAL PRODUCT

Performance	Fee
Assessment report on the feasibility of conditional reimbursement agreement, for each medicinal product separately	EUR 3,850
Assessment report on the implementation of conditional reimbursement agreement, for each medicinal product separately	EUR 3,300
The fees include all pharmaceutical forms and/or strengths of the same trade name, provided that they are covered by the same conditional reimbursement agreement.	

9 CORRESPONDING DOCUMENT KEPT AT THE FINNISH MEDICINES AGENCY

Performance	Fee
For each commencing 10 pages	EUR 8
For each commencing 10 pages subject to confidentiality	EUR 14

10 DECISIONS CONCERNING ACCESS TO DOCUMENTS OTHER THAN THOSE UNDER SECTIONS 9 AND 11 OF THE ACT ON THE OPENNESS OF GOVERNMENT ACTIVITIES

Performance	Fee
Decisions concerning access to documents other than those under sections 9 and 11 of the Act on the Openness of Government Activities	
Data access authorisation or extension of data materials concerning new scientific research, except when the decision concerns a thesis	EUR 385
Data access authorisation or extension of data materials associated with a thesis	EUR 220
Research is considered a thesis when the research is the thesis of an individual researcher. If an authorisation is sought for a thesis that is prepared as part of a larger research project or for several theses with a single application, a fee of EUR 350 will be charged.	EUR 55
Continuation of a previously granted data access authorisation or its review, or a decision on supplementing the research team	

11 AUTHORISATIONS, NOTIFICATIONS AND APPLICATIONS CONCERNING MEDICAL DEVICES

11.1 Authorisations and notifications concerning medical devices

Performance	Fee
Operators' role-specific first registration fee:	
<ul style="list-style-type: none"> - manufacturers established in Finland; - manufacturers of custom-made devices; - system or procedure pack assemblers; - sterilisation service providers; - authorised representatives; - importers; <ul style="list-style-type: none"> - distributors who distribute medical devices to retailers, healthcare and social welfare operators and other professional users; and - healthcare units that engage in in-house device manufacturing 	EUR 350
Application and classification decisions under Regulation (EU) 2017/745 on medical devices (MDR):	EUR 2,200
- Decision on the application of the Act pursuant to Article 4 of the MDR	EUR 550
- Decision on classification pursuant to Article 51 of the MDR	
Application and classification decisions under Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR):	EUR 2,200
- Decision on the application of the Act pursuant to Article 3 of the IVDR	EUR 550
- Decision on classification pursuant to Article 47 of the IVDR	
Exemptions:	
- Exemption concerning a medical device of MDR risk class I–IIa in Finland	EUR 2,040
- Exemption concerning a medical device of MDR risk class IIb–III in Finland	EUR 4,070
- Exemption concerning an in vitro diagnostic medical device of IVDR risk class A in Finland	EUR 1,930
- Exemption concerning an in vitro diagnostic medical device of IVDR risk class B, C and D in Finland	EUR 3,850

11.2 Notifications and applications concerning clinical investigations of medical devices and performance studies on IVD devices

Performance	Fee
Clinical investigations of medical devices:	
- An application pursuant to the MDR on a clinical investigation of a medical device of risk class I, including corresponding clinical investigations of products listed in Annex XVI	EUR 770
- An application pursuant to the MDR on a clinical investigation of a medical device of risk class IIa–III, including corresponding clinical investigations of products listed in Annex XVI	EUR 1,930
- A notification of a post-market clinical follow-up where the investigation would involve submitting subjects to additional procedures that are invasive or burdensome	EUR 770
- Substantial modifications to clinical investigations	EUR 330
Performance studies on IVD devices:	
- Application for a performance study on an IVD device pursuant to Article 58(1) of the IVDR	EUR 1,930
- A notification pursuant to Article 58(2) of the IVDR and Section 23 of the Medical Devices Act (719/2021) of a performance study of an IVD involving companion diagnostics which only uses samples not obtained from the study subjects or where such a study is carried out using samples obtained under the Biobank Act (688/2012)	EUR 220
- A notification of a post-market performance follow-up under Article 70(1) of the IVDR that involve submitting subjects to additional procedures that are invasive or burdensome	EUR 770
- Substantial modifications to the performance study of an IVD	EUR 330

11.3 Consultation by a notified body on a a drug-device combination

Performance	Fee
Opinion, devices incorporating a medicinal substance	
(MDR (EU) 2017/745, Annex XIV, Chapter II 5.2 b)	EUR 10,000
(IVDR (EU) 2017/746, Annex XIV, Chapter II, 5.2.c)	EUR 10,000

12 NAMING AND ASSESSMENT FEES CONCERNING NOTIFIED BODIES

Performance	Fee
Processing of an application by a notified body in accordance with the MDR or IVDR	EUR 30,000
Decision on the designation or change to a notified body	EUR 1,100
Periodic assessment of a notified body in accordance with the MDR or IVDR	EUR 11,000
Re-assessment of a notified body in accordance with the MDR or IVDR	EUR 20,000
Extension the competence of a notified body	EUR 7,000

13 AUTHORISATIONS AND NOTIFICATIONS RELATED TO BIOBANKING ACTIVITIES

Performance	Fee
Notification of commencement of biobanking activities	EUR 3,300
Notification of alteration to biobanking activities	EUR 330
Biobank's notification of merging of activities	EUR 1,100
Permission to transfer a biobank abroad in whole or in part	EUR 1,100
Annual fee arising from the maintenance and operating costs of the biobank register	EUR 800
Decision on the fulfilment of the prerequisites for a public disclosure	EUR 1,100
Decision issued in response to a negative decision by an ethics committee	EUR 3,300

14 AUTHORISATIONS PURSUANT TO THE ACT ON THE MEDICAL USE OF HUMAN ORGANS AND TISSUES

Performance	Fee
Permissions issued for the medical collection or use of human organs, tissues and cells in connection with the termination of pregnancy or miscarriage	EUR 770
Permissions issued for the use of cadavers in medical teaching activities	EUR 770
Permits issued for the change in the purpose for which organs, tissues, cells and tissue samples will be used	EUR 770
Decision issued in response to a negative decision by an ethics committee	EUR 3,300
Research of medical or societal importance	EUR 770

15 LICENCES GRANTED UNDER THE MEDICAL RESEARCH ACT (488/1999)

Performance	Fee
Licence for an agency engaging in research on embryos	EUR 3,300

PUBLISHED BY MINISTRY OF JUSTICE, ISSN 1455-8904